Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5.
Wang Y, Hu Q, Madri J, Rollins S, Chodera A, Matis L. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proceedings Of The National Academy Of Sciences Of The United States Of America 1996, 93: 8563-8568. PMID: 8710910, PMCID: PMC38712, DOI: 10.1073/pnas.93.16.8563.Peer-Reviewed Original ResearchConceptsNZB/W F1 miceNZB/WF1 miceLupus-like autoimmune diseaseW F1 miceF1 miceAutoimmune diseasesNew Zealand Black x New Zealand White F1 miceFemale NZB/W F1 miceFemale NZB/WF1 miceHuman systemic lupus erythematosusMonoclonal antibodiesCourse of glomerulonephritisSystemic lupus erythematosusImmune complex glomerulonephritisSystemic complement activationWhite F1 miceImmune complex nephritisMonths of ageSevere glomerulonephritisAntinuclear antibodiesComplement component C5Continuous therapyAutoimmune syndromeLupus erythematosusRenal disease